Pomalidomide Pregnancy Prevention Programme

Women of Non-ChildBearing Potential (WNCBP) Risk Awareness Form

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information.

Healthcare professionals are asked to report any suspected adverse reactions using the Yellow Card Scheme via www.mhra.gov.uk/yellowcard or by searching for MHRA Yellow Card in the Google Play or Apple App Store. Adverse reactions should also be reported to the relevant MAH.

RISK AWARENESS FORM FOR COUNSELLING THE PATIENT TO ENSURE THE PATIENT IS FULLY INFORMED ABOUT THE SAFE USE OF POMALIDOMIDE

This Risk Awareness Form is to assist you with counselling a patient before they commence pomalidomide treatment in order to ensure it is used safely and correctly. It must be completed for each woman of non-childbearing potential prior to the initiation of their pomalidomide treatment. This form must be completed by a physician experienced in managing immunomodulatory drugs.

The purpose of the Risk Awareness Form is to protect patients and any possible foetuses by ensuring that patients are fully informed of and understand the risk of teratogenicity and other adverse drug reactions associated with the use of pomalidomide. It is mandatory that women of non-childbearing potential receive counselling and education to be made aware of the risks of pomalidomide.

The form should be retained with their medical records, and a photocopy provided to the patient. It is not a contract and does not absolve anybody from his/her responsibilities regarding the safe use of the product and prevention of foetal exposure.

Warning: Pomalidomide must not be taken during pregnancy, since a teratogenic effect in humans is expected. Pomalidomide is structurally related to thalidomide. Thalidomide is a known human teratogen that causes severe life-threatening birth defects. Pomalidomide was found to be teratogenic in both rats and rabbits when administered during the period of major organogenesis. The conditions of the Pregnancy Prevention Programme must be fulfilled for all patients unless there is reliable evidence that the patient does not have childbearing potential.
If pomalidomide is taken during pregnancy, it is expected to cause severe birth defects or death to an unborn baby.

Patient Details

Patient First Name:

Patient Last Name:

Date of Birth:	DD	MM	YYYY

Counselling Date:	DD	MM	YYYY

Did you inform your patient

1) To not share the medicinal product with any other person.	Tick
2) That they should not donate blood during treatment (including during dose interruptions) and for at least 7 days following discontinuation of pomalidomide.	Tick
3) That they should return the unused capsules to the pharmacist at the end of treatment	Tick

Prescriber Confirmation

I have fully explained to the patient named above the nature, purpose and risks of the treatment associated with pomalidomide, especially the risks to women of childbearing potential.

Date of preparation of text: February 2024
Approved by MHRA: April 2024
PATH-POM-009_v.2.0

Pathfinder
Risk Management Platform

I will comply with all my obligations and responsibilities as the prescriber of pomalidomide.

Prescriber First Name:

Prescriber Last Name:

Prescriber Signature:		Date:	DD	MM	YYYY

Patient: please read thoroughly and initial the adjacent box if you agree with the statement

I understand that pomalidomide is structurally related to thalidomide, which is known to cause severe life-threatening birth defects, therefore pomalidomide is expected to be harmful to the unborn child.	Patient Initials
I understand that severe birth defects can occur with the use of pomalidomide. I have been warned by my prescriber that any unborn baby has a high risk of birth defects and could even die if a woman is pregnant or becomes pregnant while taking pomalidomide.	Patient Initials
I have read the pomalidomide Patient Brochure and understand the contents, including the information about other possible health problems (side effects) associated with the use of pomalidomide.	Patient Initials
I understand that pomalidomide will be prescribed ONLY for me. I must not share it with ANYONE.	Patient Initials
I know that I cannot donate blood while taking pomalidomide (including dose interruptions) or for at least 7 days after stopping treatment.	Patient Initials
I understand that I must return any unused pomalidomide capsules to my pharmacy at the end of my treatment.	Patient Initials
I have been informed about the thromboembolic risk and possible requirement to take thromboprophylaxis during treatment with pomalidomide.	Patient Initials

Patient Confirmation

I confirm that I understand and will comply with the requirements of the pomalidomide Pregnancy Prevention Programme, and I agree that my prescriber can initiate my treatment with pomalidomide.

I understand that in order to receive pomalidomide as part of the medical care and treatment thatI am receiving, my personal data will be collected and processed by the NHS and the relevantMarketing Authorisation Holder (i.e. the supplier of pomalidomide) and their processors, HealthBeacon plc and Pharmacare Group Ltd. I further understand that my personal data will be processed and retained in accordance with the relevant party's privacy policy, which can be found on their website.

Patient Signature:	

Date:	DD	MM	YYYY

Date of preparation of text: February 2024
Approved by MHRA: April 2024
PATH-POM-009_v.2.0

Statement of the interpreter (where appropriate)

I have interpreted the information above to the patient/parent to the best of my ability and in a way in which I believe she/he/they can understand. She/he/they agree to follow the necessary precautions to prevent an unborn child being exposed to pomalidomide.

Interpreter Signature:		**Name:** (print)	

Date:	DD	MM	YYYY

For further information, please refer to the Summary of Product Characteristics (SmPC) for the respective medicinal product from the relevant Marketing Authorisation Holders or refer to the MHRA www.mhra.gov.uk